ARTICLE | Company News

Loxo eyeing larotrectinib registration

December 20, 2016 1:19 AM UTC

Loxo Oncology Inc. (NASDAQ:LOXO) gained $6.95 (26%) to $33.86 after it disclosed a submission timeline for larotrectinib (LOXO-101) and reported new data from a Phase I study of the candidate. The company expects to submit an NDA to FDA by early 2018, with an EMA submission to follow in 2018.

In a pipeline update Monday, Loxo said it has reached 85% enrollment in its Phase II NAVIGATE trial of larotrectinib, a basket trial enrolling patients with tropomyosin receptor kinase (TRK) fusion cancers across tumor types. In 2H17, the company expects to release top-line NAVIGATE results which it said will form the basis of its NDA. The company also said FDA awarded the candidate rare pediatric disease designation to treat infantile fibrosarcoma. ...

BCIQ Company Profiles

Loxo Oncology Inc.